WO2009139853A3 - Human monoclonal antibodies against human chemokine receptor ccr7 - Google Patents

Human monoclonal antibodies against human chemokine receptor ccr7 Download PDF

Info

Publication number
WO2009139853A3
WO2009139853A3 PCT/US2009/002937 US2009002937W WO2009139853A3 WO 2009139853 A3 WO2009139853 A3 WO 2009139853A3 US 2009002937 W US2009002937 W US 2009002937W WO 2009139853 A3 WO2009139853 A3 WO 2009139853A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
monoclonal antibodies
antibodies against
chemokine receptor
receptor ccr7
Prior art date
Application number
PCT/US2009/002937
Other languages
French (fr)
Other versions
WO2009139853A2 (en
Inventor
Tajib Mirzabekov
David Kreimer
Original Assignee
Kim, Eldar
Msm Protein Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kim, Eldar, Msm Protein Technologies, Inc. filed Critical Kim, Eldar
Priority to EP09746941A priority Critical patent/EP2285403A2/en
Publication of WO2009139853A2 publication Critical patent/WO2009139853A2/en
Publication of WO2009139853A3 publication Critical patent/WO2009139853A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aspects of this invention include fully human antibodies of fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7 receptor in biological samples for diagnostic or evaluative purposes.
PCT/US2009/002937 2008-05-14 2009-05-11 Human monoclonal antibodies against human chemokine receptor ccr7 WO2009139853A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09746941A EP2285403A2 (en) 2008-05-14 2009-05-11 Human monoclonal antibodies against human chemokine receptor ccr7

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12774708P 2008-05-14 2008-05-14
US61/127,747 2008-05-14

Publications (2)

Publication Number Publication Date
WO2009139853A2 WO2009139853A2 (en) 2009-11-19
WO2009139853A3 true WO2009139853A3 (en) 2009-12-30

Family

ID=41319207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/002937 WO2009139853A2 (en) 2008-05-14 2009-05-11 Human monoclonal antibodies against human chemokine receptor ccr7

Country Status (2)

Country Link
EP (1) EP2285403A2 (en)
WO (1) WO2009139853A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069620B (en) * 2015-08-10 2022-04-26 佩普麦博有限公司 Humanized antibodies to the CCR7 receptor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101886890B1 (en) * 2010-09-28 2018-08-08 세키스이가가쿠 고교가부시키가이샤 Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US9670277B2 (en) 2011-02-24 2017-06-06 The Schepens Eye Reasearch Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US20150344580A1 (en) * 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
CA3123512A1 (en) 2018-12-18 2020-06-25 Catapult Therapeutics B.V. The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069620B (en) * 2015-08-10 2022-04-26 佩普麦博有限公司 Humanized antibodies to the CCR7 receptor

Also Published As

Publication number Publication date
WO2009139853A2 (en) 2009-11-19
EP2285403A2 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
WO2009139853A3 (en) Human monoclonal antibodies against human chemokine receptor ccr7
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
MX2008009886A (en) Antibodies that bind par-2.
MX2009009261A (en) Anti-ip-10 antibodies and methods of use thereof.
EP2500362A3 (en) Humanized antibodies against TL1A
WO2011045080A3 (en) Monoclonal antibodies to progastrin and their uses
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2010142952A3 (en) Antibodies
WO2010096434A3 (en) Specific binding proteins and uses thereof
EP2103628A4 (en) Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
WO2006099698A3 (en) Novel anti-plgf antibody
WO2011015333A3 (en) Targeting of bone marrow neovasculature
WO2010016766A3 (en) Antibodies recognizing endogenous human lgr5 and/or lgr6
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
EP2826791A3 (en) Humanized anti-C5aR antibodies
WO2009140623A3 (en) Anti-psgl-1 antibodies and methods of identification and use
WO2010043977A3 (en) Dengue virus neutralizing antibodies and uses thereof
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
WO2011047087A3 (en) Protein detection via nanoreporters
IL214779A (en) Isolated monoclonal antibody or antibody which binds an epitope on human cell adhesion molecule 1 (cadm1), methods for its preparation and use thereof in the preparation of medicaments
WO2011041319A8 (en) Specific binding proteins and uses thereof
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09746941

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009746941

Country of ref document: EP